Evaluation of efficacy of erlotinib in patients with untreated, EGFR mutation positive, untreated-locally advanced NSCLC.

Evaluation of efficacy of erlotinib in patients with untreated, EGFR mutation positive, untreated-locally advanced NSCLC. - Efficacy of erlotinib in patients with untreated-locally advanced NSCLC.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011467

Enrollment

Registered

2013-08-25

Start date

2013-08-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Untreated, EGFR mutation positive, untreated-locally advanced NSCLC.

Interventions

erlotinib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Unresectable stage IIIa or IIIb NSCLC 2)Harboring EGFR sensitive mutation 3)PS 0 or 1 4)Adequate organ functions

Exclusion criteria

Exclusion criteria: 1)Having interstitial pneumonitis 2)Uncontrolable complications

Design outcomes

Primary

Measure	Time frame
surgical resectability	—

Countries

Japan

Contacts

Public ContactNakamura Yoichi

Nagasaki University Hospital Second department of internal medicine

yi-nakamu@umin.ac.jp095-819-7273

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026